Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective increased by equities research analysts at JPMorgan Chase & Co. from $265.00 to $276.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the specialty pharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 5.95% from the company’s current price.

Other analysts also recently issued reports about the stock. Royal Bank Of Canada upped their target price on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Raymond James Financial reissued an “outperform” rating and set a $239.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Truist Financial set a $264.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday. Leerink Partners lifted their target price on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Finally, Barclays raised their price objective on Jazz Pharmaceuticals from $260.00 to $270.00 and gave the company an “overweight” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $272.74.

Jazz Pharmaceuticals Stock Up 3.5%

Shares of JAZZ stock traded up $8.91 during midday trading on Tuesday, reaching $260.49. 1,309,913 shares of the stock were exchanged, compared to its average volume of 950,240. Jazz Pharmaceuticals has a 1 year low of $105.00 and a 1 year high of $261.78. The firm has a market cap of $16.36 billion, a PE ratio of -13,019.24, a price-to-earnings-growth ratio of 0.22 and a beta of 0.32. The company’s 50 day moving average is $239.50 and its two-hundred day moving average is $207.30. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The company’s revenue for the quarter was up 15.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($8.25) earnings per share. On average, equities research analysts predict that Jazz Pharmaceuticals will post 21.9 EPS for the current year.

Insiders Place Their Bets

In related news, Director Heather Ann Mcsharry sold 2,000 shares of the company’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.00, for a total transaction of $482,000.00. Following the completion of the sale, the director owned 18,449 shares in the company, valued at approximately $4,446,209. This represents a 9.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rick E. Winningham sold 2,741 shares of the stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $241.57, for a total value of $662,143.37. Following the completion of the transaction, the director directly owned 9,567 shares in the company, valued at approximately $2,311,100.19. This represents a 22.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 13,098 shares of company stock worth $3,131,906 in the last 90 days. Insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in JAZZ. LRI Investments LLC bought a new position in Jazz Pharmaceuticals in the fourth quarter worth approximately $38,000. Danske Bank A S bought a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at $40,000. Geneos Wealth Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 137 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in Jazz Pharmaceuticals by 1,383.3% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 332 shares during the period. Finally, Leonteq Securities AG purchased a new stake in Jazz Pharmaceuticals in the fourth quarter worth about $50,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Raised outlook and strong revenue growth: Jazz reported second-quarter revenue of approximately $1.21 billion, up 15.5% year over year and above the $1.11 billion analyst estimate. The company raised its 2026 revenue forecast to approximately $4.60 billion-$4.75 billion, ahead of consensus expectations near $4.5 billion. Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Core products continued to perform: Xywav revenue increased 13% year over year, with 525 net patient additions during the quarter, while Epidiolex revenue grew 16%. Management also said it is prepared to launch Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma following FDA approval. Jazz Pharmaceuticals Reports Bullish Q2
• Positive Sentiment: Analyst support increased: Morgan Stanley and Robert W. Baird raised their price targets to $280, with “overweight” and “outperform” ratings, respectively. Needham lifted its target to $292 and maintained a “buy” rating. These revisions reflect improved confidence in Jazz’s growth outlook. Needham Raises Jazz Price Target
• Neutral Sentiment: Upcoming regulatory catalyst: Investors are awaiting the FDA’s August 25 decision date for zanidatamab, which could provide a significant new commercial opportunity if approved. Jazz Prepares for Zanidatamab FDA Decision
• Negative Sentiment: Quarterly earnings missed expectations: Adjusted EPS was $5.71, below consensus estimates ranging from $6.04 to $6.18, although it improved substantially from a loss of $8.25 per share a year earlier. Jazz Q2 Earnings Lag Estimates
• Negative Sentiment: Zepzelca withdrawal: Jazz plans to withdraw Zepzelca from the FDA’s second-line small-cell lung cancer indication, removing an established indication and potentially limiting the drug’s future revenue contribution. Jazz to Withdraw Zepzelca Indication

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.